Company Encyclopedia
View More
name
Bioshares Biotech Clinical Trials Fd
BBC.US
News
View More

Praxis Precision Medicines Stock Surges 25% In Friday Pre-Market Trading— What's Going On?

Praxis Precision Medicines' stock surged 24.81% in pre-market trading after positive results from its EMBOLD study on relutrigine for SCN2A and SCN8A DEEs. The FDA will review the data soon, influencing the timing of the NDA filing. The company also completed a pre-NDA meeting for ulixacaltamide, an essential tremor treatment. PRAX stock has risen 349.53% over six months, with a market cap of $4.75 billion, showing strong momentum.

fidelity·
US
PRAX
+2.05%
fidelity·
US
PRAX
+2.05%

Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed

Several healthcare and biotech stocks saw significant gains in after-hours trading on Thursday due to clinical updates, earnings results, and regulatory developments. Sensei Biotherapeutics surged 62.9%, Praxis Precision Medicines rose 24.8%, CooperCompanies climbed 13.0%, Vanda Pharmaceuticals gained 7.5%, Cue Biopharma increased 7.8%, and ResMed added 3.7%. Key drivers included positive clinical trial results, earnings reports, and regulatory decisions.

rttnews·
US
SNSE
+21.38%
US
VNDA
-1.33%
US
PRAX
+2.05%
rttnews·
US
SNSE
+21.38%
US
VNDA
-1.33%
US
PRAX
+2.05%

Praxis Precision Medicines Reports Positive EMBOLD Study Results for Relutrigine in SCN2A and SCN8A Epileptic Encephalopathies

Praxis Precision Medicines announced positive results from the EMBOLD study on relutrigine for SCN2A and SCN8A epileptic encephalopathies. The study was stopped early due to efficacy, and results will be presented at the American Epilepsy Society Annual Meeting on December 6, 2025. Praxis plans to meet with the FDA to discuss the study results and potential NDA filing.

Reuters·
US
PRAX
+2.05%
Reuters·
US
PRAX
+2.05%

Nuvation Bio (NUVB) bounces back 12% on impressive clinical trial result

Nuvation Bio Inc. (NYSE:NUVB) saw its stock rise by 12.05% to $8.37 following positive phase 2 clinical trial results for Safusidenib, a treatment for a type of brain tumor.

MSN·
US
NUVB
-0.72%
MSN·
US
NUVB
-0.72%

3 'Strong Buy' Stocks to Buy Today, 12/4/2025, According to Top Analysts

Top analysts recommend three 'Strong Buy' stocks: Praxis Precision Medicines (PRAX), Skyward Specialty Insurance Group (SKWD), and SailPoint (SAIL). PRAX has a 70.29% upside, SKWD a 44.31% upside, and SAIL a 40.58% upside. Analysts maintain Buy ratings with adjusted price targets. TipRanks offers tools for real-time analyst rankings and stock insights.

Tip Ranks·
US
PRAX
+2.05%
US
SKWD
+5.18%
US
SAIL
+2.21%
Tip Ranks·
US
PRAX
+2.05%
US
SKWD
+5.18%
US
SAIL
+2.21%
© 2025 Longbridge｜Disclaimer